Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. - (:unkn) unknown (AMER SOC CLINICAL ONCOLOGY, 2012)